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Objective: To evaluate the efficacy and safety of twice-daily difluprednate ophthalmic   emulsion 
0.05% (Durezol®) versus placebo administered before surgery for managing inflammation and 
pain following cataract extraction.
Methods: Eligible subjects (N = 121) were randomized 2:1 to topical treatment with 1 drop 
difluprednate or placebo administered twice daily for 16 days, followed by a 14-day   tapering 
period. Dosing was initiated 24 hours before unilateral ocular surgery. Clinical signs of 
  inflammation (anterior chamber [AC] cell and flare grade, bulbar conjunctival injection, ciliary 
injection, corneal edema, and chemosis), ocular pain/discomfort, intraocular pressure (IOP), 
and adverse events were assessed.
Results: Clearing of inflammation on day 14 (primary endpoint), defined as an AC cell grade 
of 0 (#5 cells) and a flare grade of 0 (complete absence), was achieved in a significantly 
greater percentage of subjects treated with difluprednate, compared with placebo (74.7%   vs 
42.5%; P = 0.0006). A significantly greater percentage of difluprednate-treated subjects were 
free of ocular pain/discomfort on day 14 than placebo-treated subjects (64.6% vs 30.0%; 
P = 0.0004). Three subjects (3.7%) in the difluprednate group had a clinically significant IOP 
rise (defined as $21 mmHg and a change from baseline $10 mmHg at same visit).
Conclusions: Difluprednate, administered 2 times daily starting 24 hours before cataract 
  surgery, was highly effective for managing ocular inflammation and relieving pain and discomfort 
postoperatively. Difluprednate was well tolerated and provides a convenient twice-daily option 
for managing postoperative ocular inflammation.
Keywords: difluprednate, safety, efficacy, twice daily, postoperative ocular inflammation, 
corticosteroids
Introduction
Although recent advances in cataract extraction (CE) surgery have decreased the 
physical trauma associated with ocular surgery, disruption of the blood–aqueous 
barrier during surgery can lead to postoperative ocular inflammation, increasing the 
risk of secondary ocular complications, consisting of mild iritis with increased cells 
and protein in the anterior chamber (AC). This condition is often self-limiting, but 
untreated inflammation can interfere with the patient’s visual rehabilitation, and in rare 
cases can result in complications such as cystoid macular edema, posterior capsule 
fibrosis, keratopathy, fibrin reaction, or chronic uveitis.1–3 Anti-inflammatory agents Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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are routinely prescribed to resolve signs and symptoms more 
rapidly and to improve patient comfort.
Topical corticosteroids are a very effective treatment for 
postoperative ocular inflammation since they   efficiently block 
the initial release of inflammatory mediators. In June 2008 
the US Food and Drug Administration approved difluprednate 
ophthalmic emulsion 0.05% (Durezol®; Alcon Laboratories, 
Fort Worth, Texas, USA), a strong topical   steroid, for the 
  treatment of postoperative ocular inflammation and pain – the 
first steroid to be indicated for pain associated with ocular 
surgery. The approved dosing for difluprednate is 1 drop in 
the affected eye(s) 4 times daily beginning 24 hours after 
surgery and continuing for 2 weeks, followed by twice-daily 
dosing for a week, and then tapering based on the patient’s 
response.
Two multicenter, randomized, placebo-controlled 
phase 3 (registration) trials in 438 subjects with signifi-
cant postoperative ocular inflammation (defined as more 
than 11 AC cells) demonstrated that both 4-times-daily 
and 2-times-daily difluprednate, beginning 24 hours 
after surgery, effectively reduced inflammation and pain 
compared with placebo.4 A subsequent phase 3B study 
in 124 subjects has recently shown that difluprednate 
dosed 4 times daily and started 24 hours before surgery 
was highly effective for the management of postoperative 
ocular inflammation and pain associated with CE (Sirion 
Therapeutics, Tampa, Florida, USA. ST-601-003. Nov 15, 
2007. Data on file).
The phase 3B study reported here followed a similar 
design to evaluate the efficacy and safety of a twice-daily 
regimen of difluprednate versus placebo 24 hours before 
surgery for the management of postoperative ocular inflam-
mation and pain in subjects undergoing CE with or without 
intraocular lens (IOL) implantation. The comparison to 
placebo (vehicle) allows the results obtained in this study 
to be compared with the results from the phase 3 studies, in 
which treatment with twice-daily difluprednate was begun 
24 hours after surgery in patients who presented with sig-
nificant inflammation.
Patients and methods
This was a multicenter, randomized, double-masked, placebo-
controlled, phase 3B trial conducted in accordance with the 
International Conference on Harmonisation (ICH) guidelines 
and Good Clinical Practice. The study protocol was approved 
by a central Institutional Review Board (RCRC IRB, Austin, 
Texas, USA) utilized by all study sites. Before beginning 
any study-related procedures, informed written consent 
was obtained from all subjects (or parent or guardian if the 
subject was a minor).
Male and female subjects aged 2 years or older scheduled 
to have unilateral ocular surgery were included (all were CE 
with or without IOL implantation). Subjects were excluded 
if they had a history of glaucoma or ocular hypertension in 
the study eye, had previously experienced steroid-related 
intraocular pressure (IOP) rise, or at the time of screening 
had an IOP $ 24 mmHg in the study eye. Patients were also 
excluded if they showed evidence of endogenous uveitis 
or any current corneal abrasion or ulceration in the study 
eye, or were pregnant or nursing. Prohibited   medications 
included topical ocular corticosteroids or topical   nonsteroidal 
anti-  inflammatory drugs (NSAIDs) in the study eye within 
24 hours before instillation of the test agent and throughout the 
duration of the study (although   preoperative administration 
of a topical NSAID to prevent miosis was permitted); anti-
coagulants, systemic corticosteroids, or   immunosuppressive 
drugs within 2 weeks before enrollment; periocular injection 
of any corticosteroid solution in the study eye within 4 weeks 
before instillation of the test agent; and depot corticosteroids 
within 2 months before instillation of the test agent.
Subjects were screened for eligibility from 1 to 7 days 
prior to surgery on day 0 (ie, days −7 to −1) and informed 
consent was obtained. Those who met all eligibility criteria 
were   randomized according to a computer-generated list 
in a 2:1 ratio to receive either difluprednate or its vehicle 
(placebo). The 2 test agents were identical in appearance. 
Dosing was   initiated on day −1, 24 hours before ocular 
  surgery. After screening, each subject received the test agent 
with   instructions for self-administration. Subjects instilled 
1 drop 2 times daily. The treatment period was 16 days, 
followed by a tapering period of 14 days. If the investigator 
judged that treatment response was inadequate at any time 
point, subjects were withdrawn from the trial and switched 
to another medication.
Safety and efficacy assessments were conducted on days 
1, 3 or 4, 7, 14, 28, and 35. Efficacy assessments included 
AC cell grade, AC flare, chemosis, bulbar conjunctival 
injection, ciliary injection, and corneal edema. Ocular 
pain/discomfort was assessed using a visual analogue scale 
(VAS, scale 0–100) (Table 1). The primary efficacy endpoint 
was the percentage of subjects with cleared ocular inflam-
mation, defined as an AC cell grade of 0 (#5 cells) and a 
flare grade of 0 (complete absence) on day 14. Secondary 
efficacy endpoints included (1) percentage of subjects with 
an AC cell grade of 0 and a flare grade of 0 on day 7; (2) 
percentage of subjects with a pain/discomfort score of 0 on Clinical Ophthalmology 2010:4
Table 1 Study design and criteria
Study design A phase 3B, multicenter, randomized, double-masked, placebo-controlled,  
parallel-group trial
Primary efficacy endpoint On day 14, the percentage of patients having both an anterior chamber (AC) cell grade of 0 
(count of #5 cells) and an AC flare grade of 0 (complete absence of flare)
Efficacy endpoint grading criteria AC cell counta: 
  grade 0               #5 cells 
  Grade 1               6–15 cells 
  Grade 2               16–25 cells 
  Grade 3               26–50 cells 
  grade 4                .50 cells 
AC flare: 
  grade 0                Complete absence 
  grade 1                Very slight 
  grade 2                Moderate 
  grade 3                Marked 
  grade 4                intense 
Chemosis, bulbar conjunctival injection, ciliary injection, corneal edema: 
  grade 0                Absent 
  grade 1                Mild 
  grade 2                Moderate 
  grade 3                Severe 
Ocular pain/discomfort: 
  Visual analog scale (VAS) 0–100 mm (0 = absent, 100 = maximal)
Secondary endpoint  Symptom assessment: On day 14, the percentage of patients having an ocular pain/
discomfort score of 0 based on the VAS
inclusion criteria Unilateral ocular surgery 
Age 2 years or older on day of consent 
negative urine pregnancy test, administered as deemed necessary 
Provide signed, written consent
Methods All subjects (n = 121) were randomized 2:1 to topical treatment with either difluprednate  
(n = 81) or placebo (n = 40)
Dosing regimen 1 drop of difluprednate or placebo administered 2 times daily for 16 days (initiated 24 hours 
before surgery), followed by a 14-day tapering period
aAC cell count recorded as exact number of cells observed if #15.
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day 14; (3) percentage of subjects with a pain/discomfort 
score of 0 on day 7; (4) percentage of subjects with a pain/
discomfort score of 0 on day 3 or 4; and (5) percentage of 
subjects with an AC cell grade of 0 and a flare grade of 0 on 
day 3 or 4. Safety assessments included corneal endothelial 
cell density, IOP, best-corrected visual acuity, slit lamp exami-
nation, ophthalmoscopy, comfort and tolerability assessment, 
and recording of adverse events (AEs). MedDRA terms are 
used to describe AEs.
Statistical analysis
Based on the prior results of published studies using the end-
points in this trial, a sample of 120 subjects allocated to treat-
ment in the ratio of 2 (active):1 (placebo) provides 90% power 
to detect a difference between groups of 30%. Results from 
this study were reported using descriptive   statistics – number 
of subjects (N); mean, standard   deviation or   standard error of 
the mean, median, maximum, and   minimum for continuous 
outcomes; and frequency and percentage for categorical 
variables – at each assessment time point.   Differences between 
treatment groups on   multiple endpoints were   compared in a 
hierarchical   manner to control for family-wise type 1 error. 
Specifically, these endpoints were tested in a   specified order 
(as mentioned previously) with a two-sided alpha of 0.05, 
and testing continued until a P value .0.05 was obtained.5 
The analysis of a set of 2 (active, placebo) × 2 (responder, 
nonresponder) contingency tables stratified by investigative 
site was performed using the   Mantel – Haenszel method.6 
The analysis of continuous and ordinal variables used the 
applicable parametric methods (t-test, ANOVA, ANCOVA).7 
The last (post-baseline) observation   carried forward (LOCF) 
method was adopted for measures repeated over visits; 
screening values, however, were not carried   forward. The 
intent-to-treat (ITT) population was defined as all randomized 
patients receiving the study drug who underwent surgery and 
returned for at least one postsurgical visit. The safety popula-Clinical Ophthalmology 2010:4
Indication
Treatment of inflammation and pain following ocular surgery
Screen failures
No written consent
Prohibited medicine
Keratoconjunctival
  disease
History of glaucoma or
  ocular hypertension
Subjects screened
N = 129
Subjects randomized
N = 124
ITT/safety population
N = 121
Placebo BID
n = 40
Difluprednate BID
n = 81
Completed
71 (87.7%)
Excluded from ITT
Did not undergo surgery 3
Completed
23 (57.5%)
Withdrawn
10 (12.3%)
Adverse event 4 (4.9%)
Lack of efficacy 3 (3.7%)
Protocol violation 2 (2.5%)
Consent withdrawn 1 (1.2%)
Adverse event 2 (5.0%)
Lack of efficacy 13 (32.5%)
Protocol violation 1 (2.5%)
Consent withdrawn 1 (2.5%)
Withdrawn
17 (42.5%)
Entry criteria
Unilateral ocular surgery
Age 2 years or older on day of consent
Negative urine pregnancy test, administered as deemed necessary
Provide signed, written, consent
2
1
1
1
Figure 1 Subject disposition.
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tion was defined as all randomized subjects who received at 
least 1 dose of the study drug. Efficacy results are reported 
for the ITT   population (LOCF).   Statistical   analyses were 
conducted using SAS version 9.1 (DATA, Inc., Bayou La 
Batre, AL, USA).
Results
Subjects were enrolled at 6 sites in the United States between 
January and April 2008. A total of 129 subjects were screened. 
Five were screen failures and 3 were excluded from the ITT 
because they did not undergo ocular surgery and weren’t 
dosed with the study drug. The remaining 121 subjects were 
randomized 2:1 for treatment with difluprednate twice daily 
(n = 81) or with placebo twice daily (n = 40) (Figure 1). Base-
line demographics for the ITT population are   summarized 
in Table 2.
Demographics were comparable between treatment groups 
with respect to age, ethnicity, race, iris color, and type of 
  surgery received (CE with or without IOL   implantation). The 
difluprednate group had a preponderance of female subjects 
and the placebo group a preponderance of male subjects.
As seen in Figure 1, the majority of subjects (87.7%) 
in the difluprednate group completed the study compared 
with only 57.5% of subjects in the placebo group. Of the 
subjects withdrawn from the study, significantly more 
  subjects in the placebo group (32.5%) discontinued because 
of lack of efficacy compared with only 3.7% of subjects in 
the   difluprednate group (13/40 patients vs 3/81 patients, 
  respectively, P , 0.0001). An additional 4 subjects (4.9%) 
in the difluprednate group were withdrawn because of AEs, 
as were 2 patients (5%) in the placebo group. The remaining 
reasons for withdrawal (protocol violations, consent with-
drawal) did not differ significantly between treatment groups 
(3 in the difluprednate group; 2 in the placebo group).
Efficacy results
The percentage of subjects with cleared AC inflammation, 
defined as an AC cell grade of 0 (#5 cells) and a flare grade 
Table 2 Subject demographics by treatment group, safety iTT/
safety population
Subject characteristic Difluprednate  
(n = 81)
Placebo  
(n = 40)
Mean age, years  
(standard deviation)
69.4 (9.44) 71.3 (6.62)
  range 44–86 55–87
Gender, n (%)
  Female 51 (63.0%) 14 (35.0%)
Race, n (%)
  White 68 (84.0%) 32 (80.0%)
  Black/African-American 9 (11.1%) 7 (17.5%)
  Asian  4 (4.9%) 0 (0.0%)
    Native Hawaiian/other Pacific  
islander
0 (0.0%) 1 (2.5%)
Iris color, n (%)
  Blue 24 (29.6%) 9 (22.5%)
  green 5 (6.2%) 3 (7.5%)
  gray 2 (2.5%) 0 (0.0%)
  Brown 42 (51.9%) 18 (45.0%)
  hazel 8 (9.9%) 10 (25.0%)
Surgery type, n (%)
    Cataract extraction with  
intraocular lens implantation
81 (100%) 40 (100%)Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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of 0 (complete absence), at each time point is shown in 
Figure 2. From day 7 through day 28, significantly more sub-
jects in the difluprednate group had cleared AC inflammation 
compared with the placebo group. On day 14 (the defined 
primary endpoint), 59 subjects (74.7%) in the difluprednate 
group compared with 17 subjects (42.5%) in the placebo 
group had cleared AC inflammation (P = 0.0006). At that 
time, the actual AC cell count was 0 in 44 subjects (55.7%) 
in the difluprednate group compared with 14 subjects (35%) 
in the placebo group (P = 0.0329). Analysis of the mean 
change from baseline of AC cell grade – a sensitive measure 
of improvement – showed a statistically significant response to 
treatment beginning on day 3/4 (P = 0.0073) and continuing 
through day 28 (P # 0.0001).
Compared with the placebo group, a significantly greater 
percentage of difluprednate-treated subjects reported that 
they were free from ocular pain/discomfort (defined as a 
VAS score of 0) on day 14 compared with those on placebo 
(64.6% vs 30.0%; P = 0.0004). This benefit was clinically 
and   statistically significant by day 3/4, and was sustained 
through day 28 (Figure 3). Improvements in the mean grades 
of bulbar   conjunctival injection and of ciliary injection were 
  significantly greater in the difluprednate group compared 
with the placebo group as early as day 3/4, and continuing 
through day 28 (Figure 4). Similar results were shown for 
corneal edema (Figure 5). The mean score showed notably 
greater improvement for the difluprednate   twice-daily treat-
ment group compared with the placebo group at days 7, 14, 
and 28. Interestingly, improvement in chemosis grade was 
also significantly greater in the difluprednate group on day 
28 (P = 0.0343). However, baseline chemosis levels were 
low, and the clinical significance of the change seen with 
difluprednate treatment remains to be determined.
Safety
A clinically significant IOP increase (defined as an 
observed value $21 mmHg that was also a change from 
baseline $10 mmHg at the same visit) occurred in 3 diflu-
prednate-treated subjects (3.7%); only 1 received medication 
to reduce IOP. Two other difluprednate-treated subjects were 
withdrawn from study treatment because of an IOP increase. 
Among the 9 subjects (11.1%) in the difluprednate group 
reported to have an increased IOP, 5 (6.2%) were consid-
ered related to the study drug, and 3 (3.7%) of these were 
considered clinically significant. No placebo-treated subjects 
experienced elevated IOP.
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Figure 2 Percent of subjects with cleared anterior chamber (AC) inflammation – AC cell grade of 0 (#5 cells) and a flare grade of 0 (complete absence) – at each time point.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 3 Percent of subjects with an ocular pain/discomfort score of 0 on the visual analogue scale.
Fifteen subjects (18.5%) in the difluprednate group and 
19 subjects (47.5%) in the placebo group experienced ocular 
AEs considered by the investigator to be related to the test 
article (Table 3). The most frequent of these were reduced 
visual acuity, conjunctival hyperemia, ocular hyperemia, 
  ciliary hyperemia, and eye pain. Although all were   considered 
related to the study drug, each (except for IOP increase) 
occurred more frequently in the placebo group, suggesting 
that the vast majority were the result of either surgical or 
postoperative inflammation.
No deaths or serious ocular AEs were reported in either 
treatment group. Nonocular AEs associated with any particu-
lar system organ class were observed in #2.5% of subjects in 
either treatment group. These events were mostly mild and 
transient, and gave no indication of systemic toxicity. One 
subject in the difluprednate group had a serious nonocular 
AE (gastric ulcer hemorrhage) that resulted in permanent 
study discontinuation. This event was not considered to be 
related to the study drug.
Discussion
Using a wide range of clinical indicators, this study showed 
that administration of difluprednate 2 times daily starting 
24 hours before surgery was highly effective for the manage-
ment of postoperative ocular inflammation and pain. Clinical 
resolution of AC inflammation (based on cells and flare) 
on day 14 was demonstrated, a difference both clinically 
meaningful and highly statistically significant (P = 0.0006). 
Moreover, this treatment benefit was observed as early as 
day 7 and was sustained through day 28. Ocular pain and 
discomfort was also significantly reduced in the diflupred-
nate group (P , 0.001 on day 14); this treatment benefit was 
observed early (day 3/4) and sustained through day 28. This 
is particulary impressive, since no other anti-inflammatory 
agents were used in this trial.
Based on the randomized phase 3 trials of difluprednate 
administered 2 times daily and 4 times daily starting 24 hours 
after ocular surgery in patients with significant inflammation 
at baseline,4 it was expected that twice-daily dosing beginning 
24 hours before surgery would be somewhat more effective. 
Despite the possibility that accepting subjects without regard 
to degree of inflammation could have diluted the efficacy 
results, the hypothesis was validated by this study. The 
percentage of patients in the present study using twice-daily 
dosing starting 24 hours before surgery with cleared ocular 
inflammation at day 14 was comparable to that achieved 
in the phase 3 studies: predosing (24 hours before surgery) 
with difluprednate = 74.7% versus postdosing (24 hours after 
surgery) with difluprednate = 72.7%. Patients in the present 
study had a lower mean AC cell count (18.0 cells) on day 1 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Bulbar conjunctival injection Ciliary injection
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Figure 4 Mean bulbar conjunctival injection and ciliary injection grades in the difluprednate-treated and placebo-treated subjects.
compared with the baseline value (day after surgery) reported 
for the pooled phase 3 studies (24.1 cells), in which a grade 
2 or higher was required on the day after surgery. Probably 
as a consequence of this, 30.4% of difluprednate-treated sub-
jects in the current study had AC cell counts of 0 on day 7, 
compared with 17.3% of difluprednate-treated subjects on the 
same day in the twice-daily dosing arm of the phase 3 trial.
Comparing the efficacy results from this study to those 
of the identically designed phase 3B study of 4-times-daily 
dosing suggests that the overall benefit of twice-daily 
  difluprednate, with respect to reducing ocular inflamma-
tion and pain, is similar to that achieved with 4-times-daily 
dosing. The percentage of patients with cleared ocular 
inflammation at day 14 in the 4-times-daily dosing study 
was 81.3%,   compared with 74.7% in this study. Since 
twice-daily dosing is more convenient and shows similar 
efficacy, this may improve compliance and expose patients 
to a lower total steroid dose compared with 4-times-daily 
treatment.
This study used vehicle of difluprednate as a comparator 
to allow comparison with the results from the phase 3 trial, 
which also used a vehicle comparator (control group). This 
study design has been widely adopted to provide evidence of 
anti-inflammatory efficacy in phase 3.8 This does not answer 
any questions about comparative efficacy compared with 
current therapy, except by comparison between similarly 
designed vehicle controlled studies.
Three (3.7%) subjects in the difluprednate group had 
a clinically significant increase in IOP that resolved either 
spontaneously or with appropriate medical treatment. This 
rate of IOP increase is similar to that observed when diflu-
prednate is dosed 4 times daily4 and similar to other topical 
steroids, including prednisolone and rimexolone, in similar 
clinical settings.9–11
With the exception of reversible IOP increase, the incidence 
of AEs was substantially higher in the placebo group compared 
with the difluprednate group. This was expected since subjects 
in the placebo group received no   anti-inflammatory medica-
tion and also had more   postoperative complications related to 
ocular inflammation and its associated pain and discomfort. No 
deaths and only 1 serious AE occurred during the study period: 
One subject in the difluprednate group was hospitalized with 
a bleeding gastric ulcer and was   discontinued from study; this 
event was not considered to be related to difluprednate.
In conclusion, twice-daily difluprednate, dosed alone 
(without an NSAID) beginning 24 hours before surgery, 
was well tolerated and effective for the management of 
postoperative ocular inflammation and relief of ocular 
pain and   discomfort in subjects undergoing CE when 
  compared with placebo. This study indicates that twice-daily Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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  difluprednate begun 24 hours before surgery is a convenient 
and effective approach to managing ocular inflammation 
associated with CE.
Day 3/4 Day 7 Day 14 Day 28
M
e
a
n
 
c
o
r
n
e
a
l
 
e
d
e
m
a
 
s
c
o
r
e
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.6 0.6 0.2 0.5 0.1 0.4 0 0.3
Difluprednate BID = 1.1
Corneal edema, mean baseline, day 1
Placebo BID = 1.0
P = 0.0099
P = 0.0162
P = 0.0005
Figure 5 Corneal edema, mean score (last observation carried forward).
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Table 3 Treatment-related ocular adverse events (Aes) occurring 
in $5% of subjects in either treatment group: safety population
System organ class and 
preferred term  
(MedDRA 10.0)
Number of subjects 
reporting treatment-related 
ocular AEs, n (%)
Difluprednate 
n = 81
Placebo 
n = 40
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